Extrastriatal dopaminergic abnormalities of DA homeostasis in Parkinson's patients with medication-induced pathological gambling: A [11C] FLB-457 and PET study

Impulse control disorders such as pathological gambling (PG) are a serious and common adverse effect of dopamine (DA) replacement medication in Parkinson's disease (PD). Patients with PG have increased impulsivity and abnormalities in striatal DA, in common with behavioural and substance addictions in the non-PD population. To date, no studies have investigated the role of extrastriatal dopaminergic abnormalities in PD patients with PG. We used the PET radiotracer, [11C] FLB-457, with high-affinity for extrastriatal DA D2/3 receptors. 14 PD patients on DA agonists were imaged while they performed a gambling task involving real monetary reward and a control task. Trait impulsivity was measured with the Barratt Impulsivity Scale (BIS). Seven of the patients had a history of PG that developed subsequent to DA agonist medication. Change in [11C] FLB-457 binding potential (BP) during gambling was reduced in PD with PG patients in the midbrain, where D2/D3 receptors are dominated by autoreceptors. The degree of change in [11C] FLB-457 binding in this region correlated with impulsivity. In the cortex, [11C] FLB-457 BP was significantly greater in the anterior cingulate cortex (ACC) in PD patients with PG during the control task, and binding in this region was also correlated with impulsivity. Our findings provide the first evidence that PD patients with PG have dysfunctional activation of DA autoreceptors in the midbrain and low DA tone in the ACC. Thus, altered striatal and cortical DA homeostasis may incur vulnerability for the development of PG in PD, linked with the impulsive personality trait.

[1]  Y. Kang,et al.  Regulation of dopaminergic neuron firing by heterogeneous dopamine autoreceptors in the substantia nigra pars compacta , 2011, Journal of neurochemistry.

[2]  A. Lang,et al.  Prevalence of repetitive and reward-seeking behaviors in Parkinson disease , 2006, Neurology.

[3]  S. Houle,et al.  Drug-induced deactivation of inhibitory networks predicts pathological gambling in PD , 2010, Neurology.

[4]  R. Roth,et al.  Evidence for the absence of impulse-regulating somatodendritic and synthesis-modulating nerve terminal autoreceptors on subpopulations of mesocortical dopamine neurons , 1984, Neuroscience.

[5]  M. Hallett,et al.  Mechanisms Underlying Dopamine-Mediated Reward Bias in Compulsive Behaviors , 2010, Neuron.

[6]  Mitul A Mehta,et al.  DAT1 and COMT Effects on Delay Discounting and Trait Impulsivity in Male Adolescents with Attention Deficit/Hyperactivity Disorder and Healthy Controls , 2010, Neuropsychopharmacology.

[7]  A. Strafella,et al.  Dopamine Agonists Diminish Value Sensitivity of the Orbitofrontal Cortex: A Trigger for Pathological Gambling in Parkinson's Disease? , 2009, Neuropsychopharmacology.

[8]  J. Fallon Topographic Organization of Ascending Dopaminergic Projections a , 1988, Annals of the New York Academy of Sciences.

[9]  D. Durstewitz,et al.  The ability of the mesocortical dopamine system to operate in distinct temporal modes , 2007, Psychopharmacology.

[10]  D. Zald,et al.  Dopaminergic Network Differences in Human Impulsivity , 2010, Science.

[11]  A. Lang,et al.  Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. , 2010, Archives of neurology.

[12]  Christer Halldin,et al.  A PET-study of [11C]FLB 457 binding to extrastriatal D2-dopamine receptors in healthy subjects and antipsychotic drug-treated patients , 1997, Psychopharmacology.

[13]  R. Wise Roles for nigrostriatal—not just mesocorticolimbic—dopamine in reward and addiction , 2009, Trends in Neurosciences.

[14]  Michael J. Frank,et al.  Hold Your Horses: Impulsivity, Deep Brain Stimulation, and Medication in Parkinsonism , 2007, Science.

[15]  D. Collins,et al.  Automatic 3D Intersubject Registration of MR Volumetric Data in Standardized Talairach Space , 1994, Journal of computer assisted tomography.

[16]  Thomas J. H. Chen,et al.  Manipulation of catechol-O-methyl-transferase (COMT) activity to influence the attenuation of substance seeking behavior, a subtype of Reward Deficiency Syndrome (RDS), is dependent upon gene polymorphisms: a hypothesis. , 2007, Medical hypotheses.

[17]  V. B. Domesick Neuroanatomical Organization of Dopamine Neurons in the Ventral Tegmental Area a , 1988, Annals of the New York Academy of Sciences.

[18]  L. Tremblay,et al.  Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation. , 2010, Brain : a journal of neurology.

[19]  Dardo Tomasi,et al.  Addiction circuitry in the human brain. , 2012, Annual review of pharmacology and toxicology.

[20]  J. Javitch,et al.  D2 Receptors Regulate Dopamine Transporter Function via an Extracellular Signal-Regulated Kinases 1 and 2-Dependent and Phosphoinositide 3 Kinase-Independent Mechanism , 2007, Molecular Pharmacology.

[21]  A. Lammertsma,et al.  Simplified Reference Tissue Model for PET Receptor Studies , 1996, NeuroImage.

[22]  P. Blier,et al.  Sustained Administration of Pramipexole Modifies the Spontaneous Firing of Dopamine, Norepinephrine, and Serotonin Neurons in the Rat Brain , 2009, Neuropsychopharmacology.

[23]  Antonieta Lavin,et al.  Mechanisms Underlying Differential D1 versus D2 Dopamine Receptor Regulation of Inhibition in Prefrontal Cortex , 2004, The Journal of Neuroscience.

[24]  M. Zack,et al.  Parallel roles for dopamine in pathological gambling and psychostimulant addiction. , 2009, Current drug abuse reviews.

[25]  P S Goldman-Rakic,et al.  Prominence of the dopamine D2 short isoform in dopaminergic pathways. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[26]  I. Lucki,et al.  Effects of chronic treatment with selective agonists on the subtypes of dopamine receptors , 1992, Brain Research.

[27]  V Kaasinen,et al.  Extrastriatal dopamine D2 and D3 receptors in early and advanced Parkinson’s disease , 2000, Neurology.

[28]  Valerie Voon,et al.  Parkinson disease: Impulsive choice—Parkinson disease and dopaminergic therapy , 2011, Nature Reviews Neurology.

[29]  M. Potenza,et al.  Similarities and differences between pathological gambling and substance use disorders: a focus on impulsivity and compulsivity , 2011, Psychopharmacology.

[30]  Mark Hallett,et al.  Impulse control disorders in Parkinson's disease: recent advances. , 2011, Current opinion in neurology.

[31]  E. Hollander,et al.  The Gambling Symptom Assessment Scale (G-SAS): A reliability and validity study , 2009, Psychiatry Research.

[32]  T. Robbins,et al.  l-Dopa medication remediates cognitive inflexibility, but increases impulsivity in patients with Parkinson’s disease , 2003, Neuropsychologia.

[33]  J. Patton,et al.  Factor structure of the Barratt impulsiveness scale. , 1995, Journal of clinical psychology.

[34]  A. Benabid,et al.  Role of dopaminergic treatment in dopamine receptor down-regulation in advanced Parkinson disease: a positron emission tomographic study. , 2004, Archives of neurology.

[35]  S. Houle,et al.  Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study. , 2009, Brain : a journal of neurology.

[36]  J. Mazziotta,et al.  MRI‐PET Registration with Automated Algorithm , 1993, Journal of computer assisted tomography.

[37]  J. Seamans,et al.  The principal features and mechanisms of dopamine modulation in the prefrontal cortex , 2004, Progress in Neurobiology.

[38]  R. Passingham,et al.  Serotonin and Dopamine Play Complementary Roles in Gambling to Recover Losses , 2011, Neuropsychopharmacology.

[39]  P. Jenner,et al.  Pharmacology of dopamine agonists in the treatment of Parkinson’s disease , 2002, Neurology.

[40]  Dimitris Samaras,et al.  Oral methylphenidate normalizes cingulate activity in cocaine addiction during a salient cognitive task , 2010, Proceedings of the National Academy of Sciences.

[41]  C. Halldin,et al.  Quantification of [11C]FLB 457 Binding to Extrastriatal Dopamine Receptors in the Human Brain , 1999, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[42]  R. Narendran,et al.  Positron emission tomography imaging of amphetamine‐induced dopamine release in the human cortex: A comparative evaluation of the high affinity dopamine D2/3 radiotracers [11C]FLB 457 and [11C]fallypride , 2009, Synapse.

[43]  M. Santiago,et al.  The regulation of dopamine release from nigrostriatal neurons in conscious rats: the role of somatodendritic autoreceptors. , 1991, European journal of pharmacology.

[44]  Mary L. Schneider,et al.  High-Affinity Dopamine D2/D3 PET Radioligands 18F-Fallypride and 11C-FLB457: A Comparison of Kinetics in Extrastriatal Regions Using a Multiple-Injection Protocol , 2010, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[45]  M. Potenza,et al.  The neurobiology of pathological gambling and drug addiction: an overview and new findings , 2008, Philosophical Transactions of the Royal Society B: Biological Sciences.

[46]  Nicola J. Ray,et al.  Dopamine, Reward, and Frontostriatal Circuitry in Impulse Control Disorders in Parkinson's Disease: Insights from Functional Imaging , 2010, Clinical EEG and neuroscience.

[47]  M. Hallett,et al.  Dopamine agonists and risk: impulse control disorders in Parkinson's disease. , 2011, Brain : a journal of neurology.

[48]  A. Verma Prevalence of repetitive and rewardseeking behaviors in Parkinson disease , 2007 .

[49]  Robert Vlietinck,et al.  The Catechol-O-Methyl Transferase Val158Met Polymorphism and Experience of Reward in the Flow of Daily Life , 2008, Neuropsychopharmacology.

[50]  J. Cummings,et al.  The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment , 2005, Journal of the American Geriatrics Society.

[51]  K Suzuki,et al.  Reproducibility of [11C]FLB 457 binding in extrastriatal regions , 2001, Nuclear medicine communications.

[52]  N. Volkow,et al.  Addiction: Beyond dopamine reward circuitry , 2011, Proceedings of the National Academy of Sciences.

[53]  G. Di Chiara,et al.  6-Hydroxydopamine lesions reduce specific [3H]sulpiride binding in the rat substantia nigra: direct evidence for the existence of nigral D-2 autoreceptors. , 1987, European journal of pharmacology.

[54]  Vincent J. Cunningham,et al.  Parametric Imaging of Ligand-Receptor Binding in PET Using a Simplified Reference Region Model , 1997, NeuroImage.

[55]  A. Lang,et al.  Impulse control disorders in parkinson disease: A multicenter case–control study , 2011, Annals of neurology.

[56]  Fang Liu,et al.  Dopamine transporter cell surface localization facilitated by a direct interaction with the dopamine D2 receptor , 2007, The EMBO journal.

[57]  C. Clarke,et al.  Systematic review of levodopa dose equivalency reporting in Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.

[58]  A. Strafella,et al.  Reduced dopamine transporter density in the ventral striatum of patients with Parkinson's disease and pathological gambling , 2010, Neurobiology of Disease.

[59]  R. Kessler,et al.  Analysis of emission tomographic scan data: limitations imposed by resolution and background. , 1984, Journal of computer assisted tomography.

[60]  Lars Farde,et al.  Measurement of Methylphenidate-Induced Change in Extrastriatal Dopamine Concentration using [11C]FLB 457 PET , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[61]  N. Volkow,et al.  Dysfunction of the prefrontal cortex in addiction: neuroimaging findings and clinical implications , 2011, Nature Reviews Neuroscience.